- Home
- GBCI vs RYTM Comparison
GBCI vs RYTM Comparison
Compare GBCI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBCI
- RYTM
- Stock Information
- Founded
- GBCI 1955
- RYTM 2008
- Country
- GBCI United States
- RYTM United States
- Employees
- GBCI 3457
- RYTM N/A
- Industry
- GBCI Major Banks
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- GBCI Finance
- RYTM Health Care
- Exchange
- GBCI Nasdaq
- RYTM Nasdaq
- Market Cap
- GBCI 5.1B
- RYTM 4.3B
- IPO Year
- GBCI N/A
- RYTM 2017
- Fundamental
- Price
- GBCI $47.08
- RYTM $65.77
- Analyst Decision
- GBCI Buy
- RYTM Strong Buy
- Analyst Count
- GBCI 6
- RYTM 12
- Target Price
- GBCI $50.83
- RYTM $77.50
- AVG Volume (30 Days)
- GBCI 802.8K
- RYTM 631.5K
- Earning Date
- GBCI 07-17-2025
- RYTM 08-05-2025
- Dividend Yield
- GBCI 2.80%
- RYTM N/A
- EPS Growth
- GBCI 7.02
- RYTM N/A
- EPS
- GBCI 1.87
- RYTM N/A
- Revenue
- GBCI $827,816,000.00
- RYTM $136,863,000.00
- Revenue This Year
- GBCI $9.03
- RYTM $37.56
- Revenue Next Year
- GBCI $14.29
- RYTM $74.99
- P/E Ratio
- GBCI $25.19
- RYTM N/A
- Revenue Growth
- GBCI 8.47
- RYTM 48.88
- 52 Week Low
- GBCI $35.57
- RYTM $40.46
- 52 Week High
- GBCI $60.67
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- GBCI 71.49
- RYTM 57.57
- Support Level
- GBCI $42.68
- RYTM $60.80
- Resistance Level
- GBCI $43.98
- RYTM $67.75
- Average True Range (ATR)
- GBCI 1.09
- RYTM 2.08
- MACD
- GBCI 0.58
- RYTM 0.26
- Stochastic Oscillator
- GBCI 97.40
- RYTM 71.91
About GBCI Glacier Bancorp Inc.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.